Aventine develops evidence-based, transparent, pharmacoeconomic models for US payers, focusing on budget impact and cost-effectiveness analyses.
There is growing recognition that a comprehensive economic assessment of a new health-care intervention requires both a cost-effectiveness analysis and a budget impact analysis.1,2 In fact, many US payers are requesting both analyses when a product is submitted for coverage determination.2-4
Aventine develops evidence-based, transparent, pharmacoeconomic models for US payers, frequently in tandem with dossier development. Aventine has developed economic models across a wide range of products and disease states.
Aventine models are developed and delivered in Microsoft Excel®. Microsoft Visual Basic® is used to generate macros and control features as required. All calculations are presented such that our models provide complete transparency. Aventine-developed models are always interactive, allowing users to most closely simulate their member population’s characteristics, utilization, and costs.
Aventine Therapeutic Experience by Economic Modeling Type
|Budget Impact Analyses||Cost-Effectiveness or
Budget Impact Models
The purpose of a budget impact model is to estimate the financial consequences of adoption and diffusion of a new healthcare intervention within the context of a specific healthcare setting or system given inevitable resource constraints.1,2 However, budget impact models are not intended to establish the overall value of a product because they do not include the full impact of the product on clinical and patient outcomes.4 Therefore, they are useful for estimating the impact on the pharmacy and/or medical budgets (eg, its affordability) and are frequently used by managed care payers.4
The purpose of a cost-effectiveness analysis is to assess the overall clinical risk-benefit and economic value of a product in relation to products in the class and other healthcare interventions in general; it estimates the product’s economic efficiency.2,4
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. Jan-Feb 2014;17(1):5-14.
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health. Sep-Oct 2007;10(5):336-347.
- WellPoint. Health Technology Assessment Guidelines: Drug submission guidelines for new products, new indications, and new formulations. 2008.
- FMCP Format Executive Committee. The AMCP Format for Formulary Submissions: Version 3.1. December 2012.
“Thank you all your efforts and expertise developing and delivering the AMCP Dossier. Great work!”- D.S. – Medical Director, Medical Affairs
“I’m very glad we have Aventine as a partner!”- G.B. – Senior Manager, Global Health Economics & Outcomes Research
“That is great news to have the final version! Thank you for delivering an outstanding document and BIM to support our launch efforts. Count me as one of your biggest fans.”- A.P. – VP, Medical Affairs
“The BIM looks good and I agree with your logic! Thanks!”- M.T. – Manager, Health Economics & Outcomes Research
“Simple, yet concise, complete and compelling! You make my job easier and I can’t wait for today’s presentation!”- I.T. – VP, Patient Access & Quality
“The US (and Canadian documents) are well done and feedback from the team has been very positive.”- R.Y. – Medical Information Specialist
“I also want to provide some extremely positive feedback to you and your team. As previously discussed, we needed to provide an early draft copy to our partners…to assist their efforts and support for our Compendia application. They have someone on their team who is reported to be the most experienced “expert” on all matters related to the Compendia, not currently employed there, having over 20 years of prior experience working for the Compendia. Likewise, in both roles, she has reviewed more than a few dossiers over the years. She provided great praises and compliments to the dossier draft related to the quality of writing, flow, content, appropriate length, and lack of fluff, noting it was one of the best dossiers she had seen. Thank you for providing such a high quality document. The final graphics will enhance the look, but you’ve already hit a homerun on the content!! THANK YOU!”- A.P. – VP, Medical Affairs
“Thank you for really hustling, Holly. You and your team are OUTSTANDING!”- M.B.S. – Senior Manager, Global Health Economics and Outcomes Research
“It [the dossier update] was an amazing refresh where yours and your teams efforts made it read better, clearer, etc. [vs prior non-Aventine version] and it will be much more useful for end readers (ie formulary decision makers!)”- S.P. – Senior Director, Health Economics and Outcomes Research
“Many thanks for your great work! Our colleagues were all impressed by the quality of the work, and many (including me) did not have any extra comments to add. Bravo for the job well-done!”- G.B. – Senior Manager, Global Health Economics & Outcomes Research
“This model looks great. Always great to be working with such fine professionals and fellow pharmacists!!”- C.B. – Senior Manager, Strategic Brand Customer Marketing
“[Our] data are quite cumbersome, especially with all the post-hocs, so I very much appreciate your hard work and attention to detail on this. Great job!!”- J.W. – Managed Care Medical Communication
“You guys did a fantastic job and it was a pleasure working with you all!”- M.H. – Vice President – Market Access
“I think the dossier looks great! I certainly appreciate all of the work you put in on this project!”- M.O. – Director, Health Economics and Outcomes Research
“I have reviewed the model and think that it looks excellent! Very nice job!!”- M.O. – Director, Health Economics and Outcomes Research
“Thanks for the quick turnaround and for all your hard work. The dossier looks great.”- E.C. – Managed Care Medical Communications
“You always exceed my expectations, thank you!”- B.G. – Senior Manager, Global Health Economics & Outcomes Research
“Nice job!!! I am impressed with the information and the excellent discussion [in the manuscript]!”- S.S. – Associate Professor of Pharmacotherapy
“You did a great job on the Dossier. Thank you again for your work on this.”- N.A. – Medical Affairs, Medical Communications and Promotional Review
“These models look great already, kudos to you & your team!”- G.B. – Senior Manager, Global Health Economics & Outcomes Research
“I can’t thank you enough for all your hard work on the dossier. I very much appreciate your flexibility, promptness, but most importantly the quality of work. It has truly been a pleasure to work with you as well and I look forward to our future collaboration.”- F.D. – Medical Communications Liason, Medical Affairs
“We definitely want you to do our [dossier] update next year. Your work is great and it’s a pleasure working with nice people like you.”- C.W. – Associate Director, Medical Information and Scientific Alliances
“It was really nice working with you on the dossier. Hope to work with you again in the future.”- K.K. – Medical Information & Review Analyst
“Thank you for your collaboration! It was great working with you to update the [product] dossier…I appreciate your patience and flexibility.”- S.Q. – Managed Care Medical Communications
“I enjoyed our discussion today and I am thrilled to be working with such a talented and experienced team on this important project.”- D.S. – Medical Director, Medical Affairs
“I truly appreciate your scientific vigor, clear communication, flexibility, and follow through! I look forward to continuing to work with you and the [Aventine] team on future projects.”- S.L. – Managed Care Medical Communications
“Thanks again for doing a fantastic job with the dossier. Always a pleasure to work with such a capable partner. “- S.F. – Associate Director Medical Information – Managed Markets
“Great work from the Aventine team! I’ve attached consolidated feedback which is very minimal from [our] team.”- M.W. – Director – Global Outcomes & Evidence
“Made it through this great dossier. Really well done!”- N.W.- Executive Director, Medical Affairs
“You are outperforming the big companies! Thank you very much for your efforts, the dossier is much improved over the previous version from the other vendor.”- R.D. – Managed Care Medical Communications
“This dossier was well-done, and our review team was extremely pleased. Thank you!”- G.B. – Senior Manager, Global Health Economics & Outcomes Research